<DOC>
	<DOCNO>NCT02369809</DOCNO>
	<brief_summary>Aim study gain knowledge efficacy safety Neovasculgen® daily clinical practice obtain information quality life patient treat Neovasculgen® .</brief_summary>
	<brief_title>Non-Interventional Post Marketing Surveillance Study Neovasculgen® Patients With Chronic Lower Limb Ischemia</brief_title>
	<detailed_description>This open , control , prospective , comparative , multicentre study design . All patient receive standard conservative therapy chronic limb ischemia without cilostazol prostaglandin without surgical endovascular vessel reconstruction . Surgical endovascular vessel reconstruction unsuitable patient</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>Male female person age 40 old Subject diagnose low limb ischemia ( FontainePokrovsky Stages IIaIII chronic limb ischemia ) Signed informed consent Any disease , opinion treat physician , affect outcome study Patients addictive disorder substance abuse Pregnancy nurse All exclusion criterion list summary product characteristic ( SmPC )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Ischemia</keyword>
</DOC>